Harvard Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary

Harvard Bioscience

12/03/2025 13:31

Harvard Bioscience Inc HBIO.OQ reported quarterly adjusted earnings of 6 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 4 cents.  The mean expectation of three analysts for the quarter was for earnings of 5 cents per share. Wall Street expected results to range from 4 cents to 6 cents per share.

Revenue fell 12.8% to $24.56 million from a year ago; analysts expected $24.15 million.

Harvard Bioscience Inc's reported EPS for the quarter was breakeven results​.

The company reported quarterly net income of $18 thousand.

Harvard Bioscience Inc shares had fallen by 63.9% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

Wall Street's median 12-month price target for Harvard Bioscience Inc is $5.50

This summary was machine generated from LSEG data March 12 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
0.05
0.06
Beat
Sep. 30 2024
0.03
-0.02
Missed
Jun. 30 2024
0.05
0.00
Missed
Mar. 31 2024
0.02
0.02
Met